Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications

Fig. 3

Validation of 22B12 mAb for detection of CD160-TM in TNBC tumor cells. a After adhesion on glass slides and fixation, TNBC cell lines were incubated with anti-CD160 mAb 22B12 followed by AlexaFluor594-coupled anti-mouse Igs antibodies. Control labeling with muIgG2a Ig was performed in parallel. Slides were mounted with a Dapi-containing medium for nuclei counterstaining (blue). Images were acquired on a Nikon Ni fluorescence microscope. Magnification: 60×. b Healthy (n = 4) or tumor (n = 10) tissue from TNBC patients was subjected to single immunostaining using 22B12 mAb. Shown are images from a representative sample (full set of images available in Additional file 1: Figure S3)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us